Sign in
Taking people in SerbiaNo phase

Structured care approach for older people with atrial fibrillation and other conditions

Tests a structured care program in older people with atrial fibrillation and several health conditions.

Key facts

Who runs it
Heart Care Foundation
Where
Belgrade, Kragujevac, and Niš, SerbiaSee the 8 sitesAlso in 5 other countries, 42 sites
Trial code
Registry title
Integrated Approach in Frail Older People with Atrial Fibrillation
Status
Recruiting
People taking part
1,250 people, planned
Started
11 Apr 2024
Planned end
31 Jan 2026
Type of study
Interventional, 2 groupsOne group gets no study treatment, for comparison.
Treatments tested
  • iABC platform use
Record updated
14 January 2025

Who can take part

AI summary

From the trial's eligibility criteria. Machine-read from the registry text on this page, so it can be wrong. The registry text below and the trial team decide who can take part.

The trial is looking for outpatients aged 65 or older with atrial fibrillation and at least one other long-term illness. It tests a structured team approach to care.

Age
65 years or older
Sex
All sexes
Disease stage
Atrial fibrillation (first diagnosed, paroxysmal, persistent, long-standing persistent or permanent), confirmed by ECG or Holter monitoring, plus at least 1 other long-term illness

Main reasons for not taking part

  • Mechanical prosthetic heart valve or moderate/severe mitral stenosis
  • Serious disease with life expectancy under 12 months
  • Unable to understand the study or attend follow-up
  • Taking part in other interventional studies
  • Unwilling to sign written informed consent

The registry criteria, word for word

Show all 9 criteriaShow less

Who can take part

  • Outpatients of both sexes with age ≥65 years
  • First diagnosed, paroxysmal, persistent, long-standing persistent or permanent AF, confirmed as per guideline-recommended diagnostic criteria for AF, e.g. with electrocardiogram (ECG) or Holter monitoring
  • ≥1 additional long-term comorbidity, thus fulfilling the definition of multimorbidity: hypertension (treated with at least 2 antihypertensive drugs), coronary artery disease (CAD), peripheral artery disease, heart failure, stroke/TIA, diabetes mellitus, COPD, CKD

Who cannot take part

  • Mechanical prosthetic heart valve or moderate/severe mitral stenosis
  • Serious diseases with a life expectancy inferior to 12 months
  • Patient unwilling to be enrolled and sign written informed consent
  • Patient unable to understand the study and attend the follow-up
  • Patients included in other interventional studies; Only for sites randomized to the iABC group:
  • Patient without a device suitable for iABC use

Where in Serbia

Also in 5 other countries, 42 sites

  • Institute for Cardiovascular Diseases Dedinje-Pacemaker and electrophysiology departmentBelgrade, SerbiaContact: DEJAN KOJIC, MDTaking people
  • KBC Bezanijska Kosa-Cardiology DepartmentBelgrade, SerbiaContact: MARIJA ZDRAVKOVIC, MDTaking people
  • KBC Zemun-Cardiology DepartmentBelgrade, SerbiaContact: RADOSAV VIDAKOVIC, MDTaking people
  • University Clinical Centre of Serbia-Department for cardiac arrhythmiasBelgrade, SerbiaContact: TATJANA POTPARA, MDTaking people
  • University Clinical Centre of Serbia-Department for invasive electrophysiologyBelgrade, SerbiaContact: NEBOJSA MUJOVIC, MDTaking people
  • University Clinical Centre of Serbia-Emergency centreBelgrade, SerbiaContact: TANJA JOZIC, MDTaking people
  • University Clinical Centre of Kragujevac-Cardiology DepartmentKragujevac, SerbiaContact: STEFAN SIMOVIC, MDTaking people
  • University Clinical Centre of Nis-Cardiology DepartmentNiš, SerbiaContact: TOMISLAV KOSTIC, MDTaking people

About the trial

What the trial wants to find out

The study will verify if a structured multidisciplinary approach (called iABC), aimed to improve the appropriate management of elderly AF patients with multimorbidity (the i-ABC group), would provide a clear evidence of an improvement in clinical conditions and quality of life compared to usual clinical care. The i-ABC group in AFFIRMO will follow the ABC pathway, focused on three domains: avoid stroke with anticoagulation (with optimized VKA or label-adherent DOAC use); better symptom management; and optimized management of associated cardiovascular and non cardiovascular comorbidities.

Read full original descriptionShow less

The study will be conducted in Bulgaria, Denmark, Italy, Romania, Serbia and Spain .

The 2 groups in the trial

  • Quality-improvement intervention (iABC)Treatment being tested

    The novel platform (iABC) that will be used in AFFIRMO will consist of an educational program, a healthy or functional diet/physical activity, guideline-adherent drug treatments, periodic (re)assessment. iABC will provide guidance to obtain a more personalized care to AF patients in the experimental cluster implementing specific strategies to obtain clinical control for all the three pillars of the ABC pathway. During the entire follow-up the physician will be able to check the data imputed by the patients and, eventually, contact the patient to provide recommendations and to discuss changes to the treatments and lifestyle habits.

    Treatment: iABC platform use

  • Usual careNo study treatment, for comparison

    Patients followed in the centers randomized to the control arm will be managed by usual care in accordance with local clinical guidance

Questions to ask the study team

  1. How often do I need to come in, and for how long each time?
  2. Are travel costs paid?
  3. Can I keep my own doctor?
  4. What happens if I want to stop?

Contact the study team: see the registry record → Contacts and Locations

Print a page for my doctor

Data and sources

Registry record
Listed on ClinicalTrials.gov.
Official title
AFFIRMO - Atrial Fibrillation Integrated Approach in Frail, Multimorbid and Polymedicated Older People
Plain-language title
Structured care approach for older people with atrial fibrillation and other conditionsGenerated from the registry record. The registry title is the official one.
AI summary
From the trial's eligibility criteria. Read by machine on 12 November 2026.
Publications
Record updated
14 January 2025